Loomis Sayles, an funding administration firm, launched its “Small Cap Value Fund” third-quarter 2025 investor letter. A duplicate of the letter might be downloaded right here. US equities delivered sturdy outcomes in the third quarter, primarily pushed by easing tariff considerations, a pro-growth price range handed by the U.S. Congress, and anticipation of the Federal Reserve’s additional fee cuts. The fund returned 6.21% in the quarter in comparison with 12.60% for the Russell 2000 Value Index. In addition, please examine the fund’s prime 5 holdings to know its finest picks in 2025.
In its third-quarter 2025 investor letter, Loomis Sayles Small Cap Value Fund highlighted shares similar to Haemonetics Corporation (NYSE:HAE). Headquartered in Boston, Massachusetts, Haemonetics Corporation (NYSE:HAE) is a medical know-how firm. The one-month return of Haemonetics Corporation (NYSE:HAE) was -0.92%, and its shares gained 3.36% of their worth over the final 52 weeks. On December 24, 2025, Haemonetics Corporation (NYSE:HAE) inventory closed at $80.01 per share, with a market capitalization of $3.855 billion.
Loomis Sayles Small Cap Value Fund said the following relating to Haemonetics Corporation (NYSE:HAE) in its third quarter 2025 investor letter:
“The market management change towards “risk-on” and “low-quality” shares is widespread round market pivot factors and has continued into the third quarter of the 12 months. Regarding our Fund, inventory choice measures trailed the index given the fashion mismatch with our top quality strategy. From a person inventory perspective Haemonetics Corporation (NYSE:HAE), Alight, Inc. and Kyndryl Holdings Incorporated detracted the most from efficiency.
Haemonetics Corporation (NYSE:HAE) will not be on our listing of 30 Most Popular Stocks Among Hedge Funds. As per our database, 36 hedge fund portfolios held Haemonetics Corporation (NYSE:HAE) at the finish of the third quarter, which was 29 in the earlier quarter. In the second quarter of fiscal 2026, Haemonetics Corporation (NYSE:HAE) reported income of $327 million, marking a 5% reported income decline. While we acknowledge the potential of Haemonetics Corporation (NYSE:HAE) as an funding, we consider sure AI shares supply better upside potential and carry much less draw back danger. If you are searching for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the finest short-term AI inventory.